Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide Priming Prior to CAR-T Therapy for RRMM
NCT07727668Phase 1Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iberdomide in multiple myeloma (MM). Primary endpoint: Proportion of patients with T cell effector memory (TEM) expansion at Day 29. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07727668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07727668.